Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

ABSTRACT: This study will include two parts: * In the phase I part: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG6002 in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors. * In the phase IIa part: evaluation of efficacy and further evaluation of safety of multiple administrations of TG6002 in combination with flucytosine (5-FC) in patients with colorectal cancer and liver metastases. In both parts, tumor response will be evaluated on local assessment using RECIST 1.1. All patients will be followed up until disease progression or death due to any cause or the date of data cut-off, whichever occurs first.

DISEASE(S): Gastrointestinal Neoplasms,Colorectal Neoplasm,Colorectal Neoplasms,Neoplasms,Digestive System Neoplasms,Digestive System Neoplasm

PROVIDER: 2288207 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A clinical study of TG6002 and flucytosine in patients with gastro-intestinal tumors

Project description:Primary objectives: Phase I: determination of the recommended phase II dose Phase IIa: efficacy of multiple administrations of TG6002 in combination with flucytosine (or Ancotil or 5-FC) Primary endpoints: Phase I: adverse events, serious adverse events, change in standard laboratory parameters and vital signs, dose-limiting toxicities. Phase IIa: overall response rate.

| 2537744 | ecrin-mdr-crc

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Project description:This study will include two parts: * Phase I part is a dose-escalation study to assess the safety of increasing doses of TG6002 in combination with oral flucytosine (5-FC) in consecutive cohorts of 3 to 6 patients with colorectal cancer and unresectable liver metastases according to a 3+3 design * Phase IIa part is an extension of the phase I part at the recommended phase II dose to evaluate the efficacy of TG6002 in combination with oral flucytosine (5-FC) in patients with colorectal cancer and unresectable liver metastases. In both parts, tumor response will be evaluated on local assessment using RECIST 1.1. All patients will be followed until disease progression, death due to any cause or the date of data cut-off, whichever occurs first.

| 2324305 | ecrin-mdr-crc

Broiler gastro-intestinal microbiome

Project description:Broiler gastro-intestinal microbiome Raw sequence reads

| PRJNA836733 | ENA

Biomarkers of human gastro-intestinal tract regions

Project description:Background and aims: Dysregulation of intestinal epithelial cells performance associates with an array of pathologies whose onset mechanisms are incompletely understood. The aim of the present study was to provide a map of gene expresssion patterns along the human healthy adult gastro-intestinal tract and to implement a new procedure for microarray data noise filtering that would allow their use as a reference when screening for pathological deviations, such as inflammatory bowel disease (IBD). Methods: Gene expression profiles in antrum, duodenum, jejunum, ileum and transverse colon biopsies were measured with the Affymetrix U133A array and principal component analysis was used to identify region-selective biomarkers. These data were intersected with highly variable genes from a public dataset of gene expression in the ileal and colonic healthy regions of UC and Crohn’s disease patients. Moreover, gene sets covering gut functions not entirely accounted for by the available public tools were constructed to monitor their expression along the GI tract. Results: 166 genes were found to be responsible for distinguishing the five regions considered. Fourteen had never been described in the GI tract, including a semaphorin probably implicated in pathogen invasion, and six other novel genes. Similar analysis of the IBD datasets revealed that samples stratify based on disease rather than on the intestinal region. This withstanding, eleven genes were identified as possible early predictors of Crohn’s and/or UC in ileum and/or colon. These include CLCA4 and SLC26A2, both implicated in ion transport. Conclusions: This novel approach, validated by retrieving known gene profiles, allowed the identification of promising new leads both in health and IBD state. Keywords: gastro-intestinal tract comparison

2010-03-20 | GSE10867 | GEO

KCNQ POTASSIUM CHANNELS MODULATE WNT ACTIVITY IN GASTRO-OESOPHAGEAL ADENOCARCINOMAS

Project description:Voltage sensitive potassium channels play an important role in controlling membrane potential and ionic homeostasis in the gut and have been implicated in gastrointestinal (GI) cancers. Through large scale analysis of 897 patients with Gastro-oesophageal adenocarcincomas (GOA) coupled with in vitro models, we find KCNQ family genes are mutated in ~30% of patients, and play therapeutically targetable roles in GOA cancer growth. KCNQ1 and KCNQ3 mediate the WNT pathway and MYC to increase proliferation through resultant effects on cadherins junctions. This also highlights novel roles for KCNQ3 in non-excitable tissues. We additionally discover that activity of KCNQ3 sensitises cancer cells to existing potassium channel inhibitors, and that inhibition of KCNQ activity reduces proliferation of GOA cancer cells. These findings reveal a novel and exploitable role for potassium channels in the advancement of human cancer, and highlight that supplemental treatments for GOAs may exist through KCNQ inhibitors.

2023-09-13 | GSE242782 | GEO

A clinical study of TG6002 and flucytosine in patients with colorectal cancer

Project description:Primary objectives: Phase I:Determination of the maximum tolerated dose (MTD) or maximum feasible dose (MFD) and the recommended dose for the Phase IIa part (RP2D).Phase IIa:Determination of the preliminary efficacy of intrahepatic artery injection of TG6002 in combination with 5-FC. Primary endpoints: Phase I:Dose-limiting toxicities, adverse events, serious adverse events, change in standard laboratory parameters and vital signs.Phase IIa:Disease control rate (DCR).

| 2538646 | ecrin-mdr-crc

FcgRIIa LC-MS/MS Supplementary Data

Project description:Supplementary Data for manuscript in Frontiers in Immunology: Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes doi: 10.3389/fimmu.2023.1260446

2023-08-30 | MSV000092799 | MassIVE

The fate of bioaccessible coeliac toxic motifs and IgE epitopes during simulated gastro-intestinal digestion of pizza base

Project description:Understanding how food processing may modify allergen bioaccessibility and the evolution of immunologically active peptides in the gastrointestinal tract is essential if knowledge-based ap-proaches to reducing the allergenicity of food is to be realised. A soy-enriched wheat-based pizza base was subjected to in vitro oral-gastro-duodenal digestion and resulting digests analysed using a combination of SDS-PAGE and mass spectrometry (MS). The digestion profile of pizza base resembled that of bread crust where higher temperatures during baking reduced protein solu-bility but still resulted in the generation of a complex mixture of peptides. MS profiling showed of the peptides carried IgE-epitopes and coeliac toxic motifs many of which were in excess of 20-30 residues long which were only released after extended (120 min) gastric digestion or a combina-tion of gastric and duodenal digestion. Comparison with in silico prediction tools showed that they either under-estimated pepsinolysis products or over estimated tryptic/chymotryptic cleavage patterns. These data show that simple thermal treatments, such as baking, are insuffi-cient to destroy the allergenic potential of wheat and soybean proteins. The findings contribute to efforts to provide bench marks for mapping in vitro digestion products of novel proteins as part of the allergenicity risk assessment.

2022-08-12 | PXD031067 | Pride

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

Project description:The study consists of the two parts, phase IIa and phase IIb.

| 2404180 | ecrin-mdr-crc

Beyond acid suppression: Novel therapeutic targets for gastro-esophageal reflux disease based on a murine model (esophageal tissue)

Project description:Background & Aims: Because the pathophysiology of GERD is not fully understood, presently used drug target only one or more of the known underlying mechanisms but are not fully effective in all patients. 1Identifying novel central targets may pave the way to develop more effective agents. Methods: A surgical model of sub-chronic reflux esophagitis was developed. Wistar rats were pretreated for 7days with omeprazole (standard proton pump inhibitor) or STW5 (herbal preparation of established efficacy in gastro-intestinal disorders). Treatment was continued for 10days after surgery, rats were sacrificed and esophagi excised. Histological, proteomic and transcriptomic methods were applied to identify reflux induced changes and treatment responses. Results: Protection against reflux induced inflammation was achieved by both test drugs. Both reduced macroscopic and microscopic lesions of the esophagi as well as most measured pro-inflammatory cytokines without significantly affecting NF-kB activity. Proteomic and transcriptomic analysis identified CINC1-3, MIP-1/3α, MIG, RANTES and IL-1β as highly relevant mediators in GERD. Other highly regulated genes were those of IL-6, CCL3, CCL7 and LOX-1. Many affected cyto-/chemokines were involved in the TREM-1 signaling pathway. The fatty acid receptor GPR84 was highly up-regulated in esophagitis but down-regulated by both drugs. This was confirmed by Western blot and immune-histochemical staining, showing for the first time expression of this receptor in esophageal tissue and its possible involvement in GERD. Conclusion: STW5 and omeprazole target a broad spectrum of molecules involved in immunological and inflammatory processes, of which IL-8 (CINC1-3), TREM-1 pathway and GPR84 are proposed to be most promising novel targets for the treatment of GERD.

2015-12-16 | GSE63401 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data